Vivacelle Bio, Inc.

Vivacelle Bio, Inc. is a biotechnology startup aiming to revolutionize fluid resuscitation with its nanoparticle technology. The company's first product, VBI-1, has shown promise in animal studies and has received FDA approval for a phase IIa clinical trial for hypovolemia due to blood loss. This is a significant milestone for the company, considering the global impact of hypovolemia, which causes over a million deaths annually.

The existing options for fluid replacements have proven to be impractical and potentially harmful. In contrast, VBI-1 represents a safer and more effective solution, acting as a new paradigm in fluid resuscitation. It not only restores blood vessel volume and reverses the effects of hypovolemia but also offers additional benefits such as modulating Nitric Oxide, reducing reperfusion injury, inhibiting the inflammatory response, and acting as an energy source.

Moreover, the company has a second product, VBI-S, targeting hypovolemia due to sepsis/septic shock, demonstrating a diverse product pipeline. With its founding year in 2013, Vivacelle Bio, Inc. is positioned in the biotechnology and healthcare industries, reflecting the importance and potential impact of its innovative solutions. The recent Series A investment of $1.17M on 30 August 2018 further supports the company's growth and development, laying a strong foundation for its future endeavors.

Based in the United States, Vivacelle Bio, Inc. is poised to make a significant contribution to the field of biotechnology and healthcare with its groundbreaking approach to addressing critical medical needs. This startup has the potential to not only save lives but also disrupt the current norms in fluid resuscitation, offering a glimpse into a promising future for the company and the patients it aims to serve.